Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)

Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2012) Jennifer J. Griggs et al.   JOURNAL OF CLINICAL ONCOLOGY

The 1000 Genomes Project: data management and community access

(2012) Laura Clarke et al.   NATURE METHODS

The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal

(2012) Paiboon Jungsuwadee et al.   Pharmacogenetics and Genomics

UGT2B7genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients

(2012) Jia-Ni Tian et al.   PHARMACOGENOMICS

ABCC1polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia

(2011) Agnes F. Semsei et al.   CELL BIOLOGY INTERNATIONAL

Physical and Psychosocial Recovery in the Year After Primary Treatment of Breast Cancer

(2011) Patricia A. Ganz et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

(2011) Henk Visscher et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing

(2011) Joke Reumers et al.   NATURE BIOTECHNOLOGY

Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients

(2010) Z. Sun et al.   ANNALS OF ONCOLOGY

In Vitro and In Vivo Inhibition of MRP Gene Expression and Reversal of Multidrug Resistance by siRNA

(2010) Zhuo Wu et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

(2010) J Bray et al.   BRITISH JOURNAL OF CANCER

Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma

(2010) Hans Wildiers et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

(2010) M.S. Aapro et al.   EUROPEAN JOURNAL OF CANCER

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients

(2009) Marie-Christine Etienne-Grimaldi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma

(2009) Jiun-I. Lai et al.   CANCER SCIENCE

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21

(2009) D Rossi et al.   LEUKEMIA

Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients

(2009) A V Khrunin et al.   PHARMACOGENOMICS JOURNAL

Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development

(2008) Shu-Feng Zhou et al.   CURRENT MEDICINAL CHEMISTRY

Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia

(2008) V Rocha et al.   LEUKEMIA

NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer

(2008) Rainer Fagerholm et al.   NATURE GENETICS

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin

(2008) Corine Ekhart et al.   Pharmacogenetics and Genomics

Impact of genetic polymorphisms inCYP2C8and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids

(2008) Julia Kirchheiner et al.   PHARMACOGENOMICS